-
UAE approves Phase II/III clinical trial of ReCOV sequential booster immunization
Time of Update: 2022-05-20
HK) announced that it has obtained Arab Clinical Trial Approval from the United Emirates National Ministry of Health and Prevention to conduct a Phase II/III clinical study of sequential boosters to evaluate the immunogenicity and safety of ReCOV as a heterologous booster in adult subjects .
-
FDA approves Bristol-Myers Squibb's Opdivo, the first NSCLC neoadjuvant therapy
Time of Update: 2022-05-20
The study data showed that the addition of Opdivo to chemotherapy in patients with stage 1b to 3a NSCLC significantly improved EFS compared to chemotherapy alone, reducing the risk of progression, recurrence or death by 37% .
-
The good news of domestic new crown drug research continues, what is the next step?
Time of Update: 2022-05-20
How to develop new crown drugs in the post-epidemic era The current mainstream methods for treating mild to moderate symptoms of new coronary pneumonia include vaccines, neutralizing antibodies, small molecule drugs, and traditional Chinese medicine .
-
Innovent Bio announced that its anti-CTLA-4 monoclonal antibody IBI310 has been included in the breakthrough therapy category by the State Drug Administration for the treatment of cervical cancer in combination with sintilimab
Time of Update: 2022-05-20
Innovent Biopharmaceutical Group (Hong Kong Stock Exchange: 01801), a biopharmaceutical company dedicated to the research and development, production and sales of innovative drugs for the treatment o
-
2 over 2 billion varieties of Sialon Pharmaceuticals were reviewed on the same day
Time of Update: 2022-05-20
Application of Consistency Evaluation of Tigecycline for Injection Source: Minet Consistency Evaluation Database Tigecycline for injection is planned to be included in the seventh batch of centralized procurement.
-
Jingyitong operation and maintenance company: Jingyitong online system will operate normally
Time of Update: 2022-05-20
We will continue to work hard to provide quality services for the majority of Jingyitong users!health health health hospital hospital hospital Beijing Yihe Spring Technology Co.
-
First completed the administration of the first subject of the Phase I clinical trial for the oral preparation of GLP-1 polypeptide XW004
Time of Update: 2022-05-20
Pan Hai, founder and CEO of Xianweida, said, "The initiation of this Phase 1 MAD clinical study is the first step in developing XW004 as a safe and effective therapy for patients with metabolic diseases .
-
VistaGen cooperates with Aimu Medical to complete the global Phase III clinical trial application of PH94B PALISADE
Time of Update: 2022-05-20
(Nasdaq: VTGN) (VistaGen) and AffaMed Therapeutics today announced that the parties have completed preparations to initiate a global Phase 3 clinical trial of PALISADE in the United States and China to To evaluate the efficacy, safety, and tolerability of PH94B (Aimu Medical AM005) when acutely administered in the treatment of adult patients with social anxiety disorder (SAD) .
-
Genetron Health Receives EU CE Qualification for Seq-MRD, a Human Lymphocyte Minimal Residual Disease Detection Product
Time of Update: 2022-05-19
On April 19, Genetron Health (Nasdaq: GTH) announced that its self-developed human lymphoid B cell minimal residual disease gene detection kit (reversible end termination sequencing method) (ie Seq-MRD®) has obtained EU CE qualification (Registration number: DE/CA20/01-IVD-Luxuslebenswelt-190/22) .
-
The sword refers to the successful phase III clinical trial of Johnson & Johnson's Stelara Amgen biosimilar drug ABP 654!
Time of Update: 2022-05-19
This is a multicenter, randomized, double-blind, comparative clinical study (Study ID: 04607980) evaluating the biosimilar ABP 654 versus Stelara (hi Dano, ustekinumab, ustekinumab) efficacy and safety .
Results showed that the study met its primary efficacy endpoint: no clinically meaningful difference between ABP 654 and Stelara .
-
Prostate cancer prevention and control situation is grim!
Time of Update: 2022-05-19
Faced with such a large risk of metastasis, timely intervention in the nmCRPC stage and delaying the patient's entry into the mCRPC stage with the worst prognosis is one of the key breakthroughs in reducing prostate cancer mortality .
-
Upatinib, the first targeted new drug for psoriatic arthritis, is here!
Time of Update: 2022-05-19
01 The real needs of patients behind the efficient approval are the key "Behind the two indications of RA and PsA that Upatinib has been approved in China, it is based on the good response of global clinical data, and it is also the reason why patients in my country have suffered from the disease for many years.
-
New Kangtec's "one person uses two drugs", although legal but not necessarily reasonable!
Time of Update: 2022-05-19
However, even if Sino-US Smith Kline has repeatedly stated in public that the two packaging indications under the "Xinkangtec" trademark are different, for patients, there is a lack of On the basis of systematic training on correct medication, there are very few cases where medication can be used for symptoms .
-
Hang Seng Pharmaceutical's Milrinone Injection Accepted
Time of Update: 2022-05-18
Source: CDE official website, Minet database A few days ago, the CDE official website showed that Hunan Hengsheng Pharmaceutical was accepted for its milrinone injection, which was reported to be a generic type 3 product .
-
100 million-level best-selling cardiovascular drug Chengdu Bitedigoxin Tablets is the first to review
Time of Update: 2022-05-18
On April 19, NMPA's official website released the latest information on approved drugs, and Chengdu Beite Pharmaceutical's digoxin tablets were the first to be reviewed .
On April 19, NMPA's official website released the latest information on approved drugs, and Chengdu Beite Pharmaceutical's digoxin tablets were the first to be reviewed .
-
Mindray Medical, the latest layout announced!
Time of Update: 2022-05-18
According to the statistics of Mindray Medical, the accessible market space corresponding to the three traditional production lines and four high-potential businesses that Mindray has deployed is 120 billion yuan and 710 billion yuan domestically and internationally .
-
$3 Billion Oral Antidiabetic Drugs!
Time of Update: 2022-05-18
Prior to this, Lepu Pharmaceuticals had won the compound antihypertensive drug Valsartan Amlodipine Tablets (I), and the total sales of this product in Chinese public medical institutions and Chinese urban physical pharmacies exceeded 2 billion yuan .
-
AstraZeneca's new crown antibody cocktail therapy can provide protection for at least 6 months in high-risk groups
Time of Update: 2022-05-17
AstraZeneca said today that its long-acting antibody cocktail, Evusheld (tixagevimab and cilgavimab), compared with placebo in a late-stage pre-exposure prophylaxis trial, reduced patients with symptomatic COVID-19 infection six months later.
-
B7-H3 Target Beacon Fire Resurrection
Time of Update: 2022-05-17
At ESMO 2021, MacroGenics announced a phase I clinical trial of MGC018 in the treatment of advanced solid tumors (cohort expansion, NCT03729596), which enrolled 86 patients, including 40 with prostate cancer, 21 with non-small cell lung cancer, and 16 with triple-negative breast cancer.
-
Sanofi Announces Summary Data from Clinical Trial of New Transplant Drug Rezurock
Time of Update: 2022-05-17
Pooled analyses from the ROCKstar (KD025-213) and KD025-028 studies show a very strong, but not generalized, correlation between organ clinical response measures and clinically meaningful changes in PRO in patients treated with Rezurock .
